ALK and non-small cell lung carcinoma: For the primary end point of IRC-assessed PFS rate at 12 months, 93.0% of patients with TKI-naive ALK-positive NSCLC did not have progression or death at 12 months (90% CI 79.2–97.8%) (Fig. 3a).